Volltextsuche
Hinweis: Bitte geben Sie einen Suchbegriff ein, z.B. "BMW", um alle Analysen und News über BMW aufgelistet zu bekommen, die innerhalb der Site von AktienCheck vorhanden sind! Zusätzlich können Sie noch eine Zeitspanne auswählen.
Suchergebnisse: (3690529 Ergebnisse gefunden) Es.
| Datum | Thema | |
|---|---|---|
| 13:10 | L'Oréal Aktie: Entscheidende Phase | |
| L'Oréal steht vor einem wegweisenden Frühjahr. Der Kosmetikriese bereitet sich auf die Veröffentlichung der ersten Quartalszahlen vor. Parallel dazu rückt die anstehende Hauptversammlung in das Blickfeld der Investoren. Die Aktie bewegt sich derzeit in schwierigem Fahrwasser. [...] | ||
| 13:05 | Mersen Aktie: Verborgene Dynamik? | |
| Mersen bewegt sich in einem Marktumfeld, das von massiven Sprüngen in der Batterietechnologie geprägt ist. Während die Automobilbranche auf effizientere Speicherlösungen drängt, rücken Zulieferer für Spezialmaterialien stärker in das Blickfeld der Märkte. [...] | ||
| 13:02 | Gilat to Report First Quarter 2026 Results on Wednesday, May 13th | |
| PETAH TIKVA, Israel, April 20, 2026 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced that it will release its first quarter 2026 financial results on Wednesday, May 13, 2026. [...] | ||
| 13:01 | Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit | |
| NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is a featured speaker at the POLITICO Health Care Summit on Tuesday, April 21. During the session, Mr. Elia will frame the evolving landscap. [...] | ||
| 13:01 | Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) | |
| Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1). [...] | ||
| 13:00 | Brady Corporation to Acquire Honeywell’s Productivity Solutions and Services Business, Expanding Portfolio with Data Capture and Workflow Solutions | |
| MILWAUKEE, April 20, 2026 (GLOBE NEWSWIRE) -- Brady Corporation (NYSE: BRC) (“Brady” or “Company”), a world leader in identification solutions, today announced that the Company has entered into a definitive agreement with Honeywell (Nasdaq: HON) to acquire Honeywell’s Productivity Solutions and Se. [...] | ||
| 13:00 | Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors | |
| Monte Rosa Presents Preclinical Data at AACR 2026 on the Potential of its Cyclin E1 (CCNE1)-directed MGDs to Treat CCNE1-amplified Solid Tumors. [...] | ||
| 13:00 | NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality | |
| WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) welcomes the newly-signed Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS, signed by President Trump on April 18, 2026. In the Order, the President notes that, “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America. [...] | ||
| 13:00 | Blossom Gold Adds World-Class Exploration Expertise to its Senior Executive Team with the Appointment of Dr. John DeDecker as Vice President, Exploration | |
| TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Blossom Gold Inc. (formerly, 1290448 B.C. Ltd.) (“Blossom” or the “Company”) (TSX: BGAU) is pleased to announce the appointment of Dr. John DeDecker as Vice President, Exploration effective April 20, 2026.. [...] | ||
| 13:00 | Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates | |
| PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels . [...] |
